A
0.655
-0.01 (-0.76%)
| Previous Close | 0.660 |
| Open | 0.655 |
| Volume | 109,737 |
| Avg. Volume (3M) | 140,256 |
| Market Cap | 83,900,912 |
| Price / Book | 4.53 |
| 52 Weeks Range |
| Profit Margin | -170.72% |
| Operating Margin (TTM) | -51.53% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | 20.50% |
| Current Ratio (MRQ) | 6.95 |
| Operating Cash Flow (TTM) | -5.10 M |
| Levered Free Cash Flow (TTM) | -3.37 M |
| Return on Assets (TTM) | -29.50% |
| Return on Equity (TTM) | -53.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ARGENICA FPO [AGN] | - | - |
AIStockmoo Score
0.4
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | 0.38 |
|
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 36.68% |
| % Held by Institutions | 0.83% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |